Planta Med 2007; 73(5): 401-420
DOI: 10.1055/s-2007-967183
Review
© Georg Thieme Verlag KG Stuttgart · New York

Natural Compounds as Inhibitors of Human Neutrophil Elastase

Bettina Siedle1 , Andrea Hrenn1 , Irmgard Merfort1
  • 1Institute for Pharmaceutical Sciences, Department of Pharmaceutical Biology and Biotechnology, University of Freiburg, Freiburg, Germany
Further Information

Publication History

Received: January 16, 2007 Revised: March 13, 2007

Accepted: March 20, 2007

Publication Date:
20 April 2007 (online)

Abstract

The imbalance between human neutrophil elastase (HNE) and endogenous serine proteinase inhibitors is considered to cause a variety of HNE-mediated inflammatory disorders. Thus, HNE has been the object of intensive research to find potent inhibitors that target its destructive and pro-inflammatory action. This review focuses on natural compounds which have been demonstrated to inhibit the enzyme itself or its release from neutrophils. Some of the natural compounds discussed here may serve as lead structures suitable to be used for the development of semi-synthetic inhibitors, but up to now none has been found active enough to be directly used in therapy.

References

  • 1 Bode W, Meyer E, Powers J C. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors.  Biochemistry. 1989;  28 1951-63.
  • 2 Tsuji N, Moriwaki S, Suzuki Y, Takema Y, Imokawa G. The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity.  Photochem Photobiol. 2001;  74 283-90.
  • 3 Nenan S, Boichot E, Lagente V, Bertrand C P. Macrophage elastase (MMP-12): a pro-inflammatory mediator?.  Mem Inst Oswaldo Cruz. 2005;  100 (Suppl 1) 167-72.
  • 4 Pham C T. Neutrophil serine proteases: specific regulators of inflammation.  Nat Rev Immunol. 2006;  6 541-50.
  • 5 Lee W L, Downey G P. Leukocyte elastase: physiological functions and role in acute lung injury.  Am J Respir Crit Care Med. 2001;  164 896-904.
  • 6 Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley T J, Abraham S N. et al . Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis.  Nat Med. 1998;  4 615-8.
  • 7 Shapiro S D. Neutrophil elastase: path clearer, pathogen killer, or just pathologic?.  Am J Respir Cell Mol Biol. 2002;  26 266-8.
  • 8 Owen C A, Campbell M A, Boukedes S S, Campbell E J. Cytokines regulate membrane-bound leukocyte elastase on neutrophils: a novel mechanism for effector activity.  Am J Physiol. 1997;  272 L385-93.
  • 9 Fitch P M, Roghanian A, Howie S E, Sallenave J M. Human neutrophil elastase inhibitors in innate and adaptive immunity.  Biochem Soc Trans. 2006;  34 279-82.
  • 10 Williams S E, Brown T I, Roghanian A, Sallenave J M. SLPI and elafin: one glove, many fingers.  Clin Sci (Lond). 2006;  110 21-35.
  • 11 Ohbayashi H. Novel neutrophil elastase inhibitors as a treatment for neutrophil-predominant inflammatory lung diseases.  IDrugs. 2002;  5 910-23.
  • 12 Bernstein P R, Edwards P D, Williams J C. Inhibitors of human leukocyte elastase.  Prog Med Chem. 1994;  31 59-120.
  • 13 Guay C, Laviolette M, Tremblay G M. Targeting serine proteases in asthma.  Curr Top Med Chem. 2006;  6 393-402.
  • 14 Döring G. Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis.  Pediatr Pulmonol. 1999;  28 363-75.
  • 15 Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects.  Lab Invest. 2000;  80 617-53.
  • 16 Meyer-Hoffert U, Wingertszahn J, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation.  J Invest Dermatol. 2004;  123 338-45.
  • 17 Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo .  J Invest Dermatol. 2002;  118 49-54.
  • 18 Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression.  Lancet Oncol. 2004;  5 182-90.
  • 19 Starcher B, O’Neal P, Granstein R D, Beissert S. Inhibition of neutrophil elastase suppresses the development of skin tumors in hairless mice.  J Invest Dermatol. 1996;  107 159-63.
  • 20 Rijken F, Kiekens R C, Bruijnzeel P L. Skin-infiltrating neutrophils following exposure to solar-simulated radiation could play an important role in photoageing of human skin.  Br J Dermatol. 2005;  152 321-8.
  • 21 Rijken F, Kiekens R C,  W E van den, Lee P L, van Weelden H, Bruijnzeel P L. Pathophysiology of photoaging of human skin: focus on neutrophils.  Photochem Photobiol Sci. 2006;  5 184-9.
  • 22 Stein R L. Catalysis by human leukocyte elastase: substrate structural dependence of rate-limiting protolytic catalysis and operation of the charge relay system.  J Am Chem Soc. 1983;  105 5111-6.
  • 23 Steinmeyer J, Kalbhen D A. Pharmacological influence on polymorphonuclear granulocytes elastase under various test conditions.  Arzneimittelforschung. 1990;  40 196-200.
  • 24 Steinmeyer J, Kalbhen D A. Influence of some natural and semisynthetic agents on elastase and cathepsin G from polymorphonuclear granulocytes.  Arzneimittelforschung. 1991;  41 77-80.
  • 25 Lestienne P, Bieth J G. Activation of human leukocyte elastase activity by excess substrate, hydrophobic solvents, and ionic strength.  J Biol Chem. 1980;  255 9289-94.
  • 26 Gao F, Du G H. Application of chemical arrays in screening elastase inhibitors.  Comb Chem High Throughput Screen. 2006;  9 381-8.
  • 27 Shen B, Shimmon S, Smith M M, Ghosh P. Biosensor analysis of the molecular interactions of pentosan polysulfate and of sulfated glycosaminoglycans with immobilized elastase, hyaluronidase and lysozyme using surface plasmon resonance (SPR) technology.  J Pharm Biomed Anal. 2003;  31 83-93.
  • 28 Cheng D H, Shen Q, Qian J, Qian Z, Ye Q Z. Expression and purification of catalytic domain of human macrophage elastase for high throughput inhibitor screening.  Acta Pharmacol Sin. 2002;  23 143-51.
  • 29 Dentener M A, Francot G J, Hiemstra P S, Tool A T, Verhoeven A J, Vandenabeele P. et al . Bactericidal/permeability-increasing protein release in whole blood ex vivo: strong induction by lipopolysaccharide and tumor necrosis factor-alpha.  J Infect Dis. 1997;  175 108-17.
  • 30 Johansson S, Goransson U, Luijendijk T, Backlund A, Claeson P, Bohlin L. A neutrophil multitarget functional bioassay to detect anti-inflammatory natural products.  J Nat Prod. 2002;  65 32-41.
  • 31 Schorr K, Rott A, Da Costa F B, Merfort I. Optimisation of a human neutrophil elastase assay and investigation of the effect of sesquiterpene lactones.  Biologicals. 2005;  33 175-84.
  • 32 Korkmaz B, Attucci S, Hazouard E, Ferrandiere M, Jourdan M L, Brillard-Bourdet M. et al . Discriminating between the activities of human neutrophil elastase and proteinase 3 using serpin-derived fluorogenic substrates.  J Biol Chem. 2002;  277 39 074-81.
  • 33 Tremblay G M, Janelle M F, Bourbonnais Y. Anti-inflammatory activity of neutrophil elastase inhibitors.  Curr Opin Investig Drugs. 2003;  4 556-65.
  • 34 Ohbayashi H. Current synthetic inhibitors of human neutrophil elastase.  Expert Opin Ther Patents. 2002;  12 65-84.
  • 35 Melzig M F, Löser B, Ciesielski S. Inhibition of neutrophil elastase activity by phenolic compounds from plants.  Pharmazie. 2001;  56 967-70.
  • 36 Sartor L, Pezzato E, Dell’Aica I, Caniato R, Biggin S, Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design.  Biochem Pharmacol. 2002;  64 229-37.
  • 37 Heilmann J, Merfort I. Current information on the metabolism of flavonoids. I. Absorption and metabolism of flavonols.  Pharm Unserer Zeit. 1998;  27 58-65.
  • 38 Heilmann J, Merfort I. Current understanding of the metabolism of flavonoids. II. Adsorption and metabolism of flavones, flavonones, flavanes, proanthocyanidens and isoflavonoids.  Pharm Unserer Zeit. 1998;  27 173-83
  • 39 Melzig M F, Pertz H H, Krenn L. Anti-inflammatory and spasmolytic activity of extracts from Droserae herba.  Phytomedicine. 2001;  8 225-9.
  • 40 Leu S J, Lin Y P, Lin R D, Wen C L, Cheng K T, Hsu F L. et al . Phenolic constituents of Malus doumeri var. formosana in the field of skin care.  Biol Pharm Bull. 2006;  29 740-5.
  • 41 Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion.  J Leukoc Biol. 2002;  71 73-9.
  • 42 Dvorakova K, Dorr R T, Valcic S, Timmermann B, Alberts D S. Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin.  Cancer Chemother Pharmacol. 1999;  43 331-5.
  • 43 Hrenn A, Steinbrecher T, Labahn A, Schwager J, Schempp C M, Merfort I. Plant phenolics inhibit neutrophil elastase.  Planta Med. 2006;  72 1127-31.
  • 44 Hamburger M, Riese U, Graf H, Melzig M F, Ciesielski S, Baumann D. et al . Constituents in evening primrose oil with radical scavenging, cyclooxygenase, and neutrophil elastase inhibitory activities.  J Agric Food Chem. 2002;  50 5533-8.
  • 45 Loeser B, Kruse S O, Melzig M F, Nahrstedt A. Inhibition of neutrophil elastase activity by cinnamic acid derivatives from Cimicifuga racemosa .  Planta Med. 2000;  66 751-3.
  • 46 Melzig M F, Löser B, Lobitz G O, Tamayo-Castillo G, Merfort I. Inhibition of granulocyte elastase activity by caffeic acid derivatives.  Pharmazie. 1999;  54 712.
  • 47 Siedle B, Murillo R, Hucke O, Labahn A, Merfort I. Structure activity relationship studies of cinnamic acid derivatives as inhibitors of human neutrophil elastase revealed by ligand docking calculations.  Pharmazie. 2003;  58 337-9.
  • 48 Takenaka M, Nagata T, Yoshida M. Stability and bioavailability of antioxidants in garland (Chrysanthemum coronarium L.)  Biosci Biotechnol Biochem. 2000;  64 2689-91.
  • 49 Boje K, Lechtenberg M, Nahrstedt A. New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase.  Planta Med. 2003;  69 820-5.
  • 50 Kacem R, Meraihi Z. Effects of essential oil extracted from Nigella sativa (L.) seeds and its main components on human neutrophil elastase activity.  Yakugaku Zasshi. 2006;  126 301-5.
  • 51 Braga P C, Dal Sasso M, Culici M, Bianchi T, Bordoni L, Marabini L. Anti-inflammatory activity of thymol: inhibitory effect on the release of human neutrophil elastase.  Pharmacology. 2006;  77 130-6.
  • 52 Siedle B, Cisielski S, Murillo R, Löser B, Castro V, Klaas C A. et al . Sesquiterpene lactones as inhibitors of human neutrophil elastase.  Bioorg Med Chem. 2002;  10 2855-61.
  • 53 Siedle B, Gustavsson L, Johansson S, Murillo R, Castro V, Bohlin L. et al . The effect of sesquiterpene lactones on the release of human neutrophil elastase.  Biochem Pharmacol. 2003;  65 897-903.
  • 54 Hernandez V, Manez S, Recio M C, Giner R M, Rios J L. Anti-inflammatory profile of dehydrocostic acid, a novel sesquiterpene acid with a pharmacophoric conjugated diene.  Eur J Pharm Sci. 2005;  26 162-9.
  • 55 Mitaine-Offer A C, Hornebeck W, Sauvain M, Zeches-Hanrot M. Triterpenes and phytosterols as human leucocyte elastase inhibitors.  Planta Med. 2002;  68 930-2.
  • 56 Safayhi H, Rall B, Sailer E R, Ammon H P. Inhibition by boswellic acids of human leukocyte elastase.  J Pharmacol Exp Ther. 1997;  281 460-3.
  • 57 Ying Q L, Rinehart A R, Simon S R, Cheronis J C. Inhibition of human leucocyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes.  Biochem J. 1991;  277 521-6.
  • 58 Ashe B M, Zimmerman M. Specific inhibition of human granulocyte elastase by cis-unsaturated fatty acids and activation by the corresponding alcohols.  Biochem Biophys Res Commun. 1977;  75 194-9.
  • 59 Rennert B, Melzig M F. Free fatty acids inhibit the activity of Clostridium histolyticum collagenase and human neutrophil elastase.  Planta Med. 2002;  68 767-9.
  • 60 Tyagi S C, Simon S R. Inhibitors directed to binding domains in neutrophil elastase.  Biochemistry. 1990;  29 9970-7.
  • 61 Edwards J V, Howley P, Cohen I K. In vitro inhibition of human neutrophil elastase by oleic acid albumin formulations from derivatized cotton wound dressings.  Int J Pharm. 2004;  284 1-12.
  • 62 Becker M, Franz G, Alban S. Inhibition of PMN-elastase activity by semisynthetic glucan sulfates.  Thromb Haemost. 2003;  89 915-25.
  • 63 Cadene M, Boudier C, de Marcillac G D, Bieth J G. Influence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor.  J Biol Chem. 1995;  270 13 204-9.
  • 64 Spencer J L, Stone P J, Nugent M A. New insights into the inhibition of human neutrophil elastase by heparin.  Biochemistry. 2006;  45 9104-20.
  • 65 Brown R A, Lever R, Jones N A, Page C P. Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro .  Br J Pharmacol. 2003;  139 845-53.
  • 66 Fook J M, Macedo L L, Moura G E, Teixeira F M, Oliveira A S, Queiroz A F. et al . A serine proteinase inhibitor isolated from Tamarindus indica seeds and its effects on the release of human neutrophil elastase.  Life Sci. 2005;  76 2881-91.
  • 67 Blackburn W D, Heck L W, Wallace R W. The bioflavonoid quercetin inhibits neutrophil degranulation, superoxide production, and the phosphorylation of specific neutrophil proteins.  Biochem Biophys Res Commun. 1987;  144 1229-36.
  • 68 Carini M, Stefani R, Aldini G, Ozioli M, Facino R M. Procyanidins from Vitis vinifera seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release.  Planta Med. 2001;  67 714-7.
  • 69 Vasange M, Liu B, Welch C J, Rolfsen W, Bohlin L. The flavonoid constituents of two Polypodium species (Calaguala) and their effect on the elastase release in human neutrophils.  Planta Med. 1997;  63 511-7.
  • 70 Hwang T L, Leu Y L, Kao S H, Tang M C, Chang H L. Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway.  Free Radic Biol Med. 2006;  41 1433-41.
  • 71 Rotondo S, Rajtar G, Manarini S, Celardo A, Rotilio D, de Gaetano G. et al . Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function.  Brit J Pharmacol. 1998;  123 1691-9.
  • 72 Tou J S. Differential regulation of phosphatidic acid (PA) formation and degranulation by polyphenolic antioxidants in stimulated human neutrophils.  Faseb J. 2002;  16 A538-9.
  • 73 Gongora L, Giner R M, Manez S, Recio M C, Schinella G, Rios J L. Effects of caffeoyl conjugates of isoprenyl-hydroquinone glucoside and quinic acid on leukocyte function.  Life Sci. 2002;  71 2995-3004.
  • 74 Feisst C, Franke L, Appendino G, Werz O. Identification of molecular targets of the oligomeric nonprenylated acylphloroglucinols from Myrtus communis and their implication as anti-inflammatory compounds.  J Pharmacol Exp Ther. 2005;  315 389-96.
  • 75 Feisst C, Werz O. Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin.  Biochem Pharmacol. 2004;  67 1531-9.
  • 76 Giannini C, Debitus C, Lucas R, Ubeda A, Paya M, Hooper J N. et al . New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions.  J Nat Prod. 2001;  64 612-5.
  • 77 Hornebeck W, Moczar E, Szecsi J, Robert L. Fatty acid peptide derivatives as model compounds to protect elastin against degradation by elastases.  Biochem Pharmacol. 1985;  34 3315-21.
  • 78 Melzig M F, Tran G D, Henke K, Selassie C D, Verma R P. Inhibition of neutrophil elastase and thrombin activity by caffeic acid esters.  Pharmazie. 2005;  60 869-73.
  • 79 Knight W B, Chabin R, Green B. Inhibition of human serine proteases by substituted 2-azetidinones.  Arch Biochem Biophys. 1992;  296 704-8.
  • 80 Dell’Aica I, Sartor L, Galletti P, Giacomini D, Quintavalla A, Calabrese F. et al . Inhibition of leukocyte elastase, polymorphonuclear chemoinvasion, and inflammation-triggered pulmonary fibrosis by a 4-alkyliden-beta-lactam with a galloyl moiety.  J Pharmacol Exp Ther. 2006;  316 539-46.
  • 81 Pochet L, Frederick R, Masereel B. Coumarin and isocoumarin as serine protease inhibitors.  Curr Pharm Des. 2004;  10 3781-96.
  • 82 Hwang T L, Yeh S H, Leu Y L, Chern C Y, Hsu H C. Inhibition of superoxide anion and elastase release in human neutrophils by 3’-isopropoxychalcone via a cAMP-dependent pathway.  Br J Pharmacol. 2006;  148 78-87.
  • 83 Verma R P, Hansch C. An approach towards the quantitative structure-activity relationships of caffeic acid and its derivatives.  Chembiochem. 2004;  5 1188-95.
  • 84 Steinbrecher T, Case D A, Labahn A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase.  J Med Chem. 2006;  49 1837-44.
  • 85 Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation.  J Intern Med. 2005;  257 319-28.
  • 86 Tsukahara K, Nakagawa H, Moriwaki S, Takema Y, Fujimura T, Imokawa G. Inhibition of ultraviolet-B-induced wrinkle formation by an elastase-inhibiting herbal extract: implication for the mechanism underlying elastase-associated wrinkles.  Int J Dermatol. 2006;  45 460-8.

Prof. Dr. I. Merfort

Institute for Pharmaceutical Sciences

Department of Pharmaceutical Biology and Biotechnology

University of Freiburg

Stefan-Meier-Str. 19

79104 Freiburg

Germany

Phone: +49-761-203-8373

Fax: +49-761-203-8383

Email: irmgard.merfort@pharmazie.uni-freiburg.de

    >